slides · global inventory
Consultants Gambit
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 39,432
Current window 34,111-34,140
Pages 1,315
Rows per page 30
Arc
34,111-34,140 of 39,432
01
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & Context1 hit
02
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & Context1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & Context1 hit
04
The slide highlights two distinct pipelines: N-GENIUS (cell therapy) and SMARxT (tissue-specific).Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & Context1 hit
05
The slide uses a stylized area chart to represent market segments and their associated financial opportunities.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem & Complication1 hit
06
The table uses a standard pharmaceutical pipeline layout with clinical and preclinical segments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem & Complication1 hit
07
The slide uses a hub-and-spoke diagram to illustrate the negative consequences of neurotoxicity.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
08
Includes a cartoon liver character, likely representing the target organ or safety profile.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
09
Includes extensive disclaimer text regarding cross-trial comparison limitations.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
10
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
11
Includes detailed source citations in the footer; uses a color-coded legend for different drug treatments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
12
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
13
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
14
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
15
The slide uses a table structure to contrast clinical outcomes across three key value pillars: response rates, tolerability, and outpatient feasibility.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
16
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
17
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
18
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
19
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
21
The slide uses a red dashed box to highlight the core clinical data rows for comparison.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
22
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
25
Includes a fashion runway photo as a visual element.Kering | Results Presentation Deck | 42 slides · Kering
Conference presentation Investor relations Beat · Evidence & ProofLoop · Golden Circle1 hit
26
Kering | Results Presentation Deck | 42 slidesKering | Results Presentation Deck | 42 slides · Kering
Conference presentation Investor relations Beat · Evidence & Proof1 hit
27
The slide uses a waterfall chart to explain revenue growth and a table for key financial metrics.Kering | Results Presentation Deck | 42 slides · Kering
Conference presentation Investor relations Beat · Evidence & Proof1 hit
28
The table displays key financial metrics including revenue, margins, and net income figures in millions of euros.Kering | Results Presentation Deck | 42 slides · Kering
Conference presentation Investor relations Beat · Evidence & Proof1 hit
29
Kering | Results Presentation Deck | 42 slidesKering | Results Presentation Deck | 42 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
30
The chart shows the movement of net debt including the impact of FCF, acquisitions, dividends, interest, and lease repayments.Kering | Results Presentation Deck | 42 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
31
Kering | Results Presentation Deck | 42 slidesKering | Results Presentation Deck | 42 slides · Kering
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
32
The slide uses a high-fashion photography background with the Pomellato logo visible in the background.Kering | Results Presentation Deck | 42 slides · Kering
Conference presentation Investor relations Beat · Impact & Next Steps1 hit